April 27, 2017 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Liabilities of $9,758,000 USD. Previously, on May 10, 2018, La Jolla Pharmaceutical Co. reported Liabilities of $29,488,000 USD. This represents a change of -66.91% in Liabilities.

Period EndPeriodValue
2016-12-31 2016-Q4 9,758,000
2018-03-31 2018-Q1 29,488,000
2017-12-31 2017-Q4 31,337,000
AllocatedShareBasedCompensationExpense CostsAndExpenses GeneralAndAdministrativeExpense IncomeTaxExaminationPenaltiesAndInterestExpense IncomeTaxExpenseBenefit IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets LeaseAndRentalExpense OtherNonoperatingIncomeExpense PrepaidExpenseAndOtherAssetsCurrent ResearchAndDevelopmentExpense RevenueFromRelatedParties Revenues WarrantGrantstoThirdPartiesCompensationExpense

Related News Stories

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-16 seekingalpha
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-4)

CUSIP: 503459604